Clinical Trial

Human Milk Concentrating Device to Optimize Mother's Own Milk

Study acronym: NEOMOM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is a randomized, non-inferiority clinical trial evaluating a human milk concentration (HMC) device in preterm infants. The trial compares outcomes in infants fed mother's own milk (MOM) concentrated using the HMC device to those receiving standard of care feeding with MOM supplemented with cow's milk-based fortifiers or formula. The primary objective is to determine whether infants receiving HMC-concentrated MOM achieve growth and mineral status that are non-inferior to standard of care, as measured by growth velocity through 28 days of life or hospital discharge and serum phosphate levels at 14 days of life. Secondary objectives include assessment of clinical safety through evaluation of feeding tolerance, weight gain, and serum chemistries during the study period. The study will also evaluate the cost and resource utilization associated with feeding strategies by comparing preparation time, supply costs, total feeding costs, and overall neonatal intensive care unit (NICU) cost of care, including length of stay.
Trial Details
NCT Number NCT07576972
Lead Sponsor Mother's Milk is Best
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Beth Israel Deaconess Medical Center, Weill Medical College of Cornell University, Yale University
Conditions Preterm Infant Health, Premature Babies
Enrollment 310 participants
Start Date 2026-09-01
Primary Completion 2027-03-14 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08